We examined the clinical safety and efficacy of F105 in 11 subjects with moderate dyslipidemia. F105 is a combination of bergamot fruit extract (Citrus bergamia, BFE) and 9 phytoextracts selected for their ability to improve the antioxidant and anti-inflammatory activity of BFE. In vitro F105 exhibited a synergistic inhibition of oxygen radical absorbing capacity, peroxynitrite formation, and myeloperoxidase activity. Following 12 weeks of F105 daily, no treatment-related adverse events or changes in body mass were seen. Statistically significant changes were noted in total cholesterol (−7.3%), LDL-cholesterol (−10%), non-HDL cholesterol (−7.1%), cholesterol/HDL (−26%), and apolipoprotein B (−2.8%). A post hoc analysis of 8 subjects with HbA1c > 5.4 and HOMA-IR score > 2 or elevated triglycerides revealed additional statistically significant changes in addition to those previously observed in all subjects including triglycerides (−27%), oxLDL (−19%), LDL/HDL (−25%), triglycerides/HDL (−27%), oxLDL/HDL (−25%), and PAI-1 (−37%). A follow-up case report of a 70-year-old female patient, nonresponsive to statin therapy and placed on F105 daily, demonstrated improved cardiometabolic variables over 12 weeks similar to the subgroup. In summary, F105 was clinically well-tolerated and effective for ameliorating dyslipidemia in subjects with moderate cardiometabolic risk factors, particularly in the individuals with HbA1c > 5.4%.
Introduction
Coronary artery disease (CAD) arising from atherosclerosis is a leading cause of death and morbidity worldwide (Weber and Noels 2011) . Multiple lines of evidence suggest that both oxidative stress and inflammation participate in a vicious cycle that can lead to impaired vascular function and CAD (Wadley et al. 2013) .
Chronic low-grade inflammation increases free radical production, causing oxidative stress in the cell (Mangge et al. 2014; Soory 2012; Stoner et al. 2013 ). This oxidative stress can further exacerbate the systemic inflammation at the cellular level, providing a basis for the progression of CAD. Consistent with this viewpoint, evidence that oxidized low-density lipoprotein (oxLDL), a pro-inflammatory mediator, induces a number of pro-atherosclerotic effects including endothelial activation and smooth muscle proliferation is accumulating (Coffey et al. 1995; Itabe et al. 2011; Li et al. 2003; Shen and Sevanian 2001; Thum and Borlak 2008) . Moreover, the oxidative modification of LDL to form oxLDL is now believed to be critically important and possibly obligatory in the pathogenesis of the atherosclerotic lesion (Hansson et al. 2006; Mitra et al. 2011a ). Thus, inhibiting the generation of reactive oxidants in addition to lowering cholesterol may be of benefit to individuals at risk of developing atherosclerosis.
It is generally believed that bioactive phytochemicals can play an important therapeutic role in attenuating oxidative damage induced by atherogenic dyslipidemia and a pro-inflammatory, pro-thrombotic state (Mangge et al. 2014) . Accordant with previous clinical findings that smaller amounts of a variety of phytochemicals have greater beneficial effects than larger amounts of fewer phytochemicals (Thompson et al. 2006) , we developed F105, a proprietary blend of bergamot (Citrus bergamia Risso) fruit extract (BFE) plus 9 botanically based antioxidants to provide breadth and diversity in the antioxidant and anti-inflammatory capability of a BFE.
Bergamot is an endemic plant of the Calabrian region in southern Italy with a unique profile of flavonoids and flavonoid glycosides present in its juice and albedo, such as neoeriocitrin, neohesperidin, naringin, rutin, neodesmin, rhoifolin, and poncirin (Gliozzi et al. 2014b) . While this fruit is primarily used in the fragrance industry for its essential oil extracted from its peel, recent studies on the juice from the endocarp of bergamot have shown that it has several bioactivities such as antioxidant, antiinflammatory, cytotoxic, neuroprotective, as well as hypolipidemic and hypoglycemic properties (Currò et al. 2016; Impellizzeri et al. 2015; Miceli et al. 2007 ; Mollace et al. 2008; Risitano et al. 2014; Sicari et al. 2016; Trovato et al. 2010; Tundis et al. 2012) . From clinical and mechanistic studies, it has been proposed (Mollace et al. 2011 ) that melitidine and brutieridine in concert with naringin and other flavonone glycosides might be responsible for the hypolipidemic effects of BFE and function as do the statin drugs through the direct action on 3-hydroxy-3-methyl-glutaryl -coenzyme A (HMG-CoA) reductase activity.
One aim of this study was to find the optimal BFE formulation in vitro that broadens the known antioxidant, anti-inflammatory, and hypolipidemic properties of BFE through the addition of a variety of known antioxidant phytocomplexes. Another aim of this study was to evaluate the clinical safety and efficacy of the BFE formulation by performing a pilot observational human study. Critical to the development of therapeutic antioxidant combinations, is the determination of optimal proportions based on synergistic interactions and increased overall activity, while avoiding antagonism. In this study, we report the synergistic antioxidant activity of F105 for inhibition of oxygen radical absorbance capacity (ORAC), peroxynitrite (ONOO − ) scavenging capacity, and inhibition of myeloperoxidase (MPO) activity. Secondly, a pilot observational clinical study was conducted to investigate the safety and efficacy of F105 in human subjects with moderate cardiometabolic risk factors. Additionally, a case management study with a 70-year-old female patient, nonresponsive to statin therapy and placed on F105 daily, was also conducted.
Materials and methods

Test material
A version of the test material developed and used in the present studies is commercially available as the nutraceutical Cardiox-LDL, which contains 250 mg of BFE (HP Ingredients, Bradenton, Florida, USA.) and 110 mg of a blend of 9 other phytoextracts: apple fruit extract (Botanical Therapeutics, Walnut, California, USA), blueberry fruit concentrate (Van Drunen Farms, Momence, Illinois, USA.), capsicum fruit (BDS Natural, Carson, California, USA), grape seed extract (Polyphenolics, Madera, California, USA), grape skin extract (Naturex, South Hackensack, New Jersey, USA), green tea leaf extract (BI Nutraceuticals, Rancho Dominguez, California, USA), mangosteen pericarp extract (Azile LLC, Rolling Hills Estates, California, USA), olive leaf extract (Natac Biotech, Salt Lake City, Utah, USA), and turmeric root & rhizome extract (Sabinsa, Payson, Utah, USA) per capsule. Samples of all authenticated raw materials in F105 and the commercial product are retained for 7 years past the manufacture date in Nature's Sunshine facilities (Lehi, Utah, USA) .
The F105 test material was initially formulated by combining apple fruit extract, bergamot fruit extract, blueberry fruit concentrate, capsicum fruit, grape seed extract, grape skin extract, green tea leaf extract, mangosteen pericarp extract, olive leaf extract, and turmeric root & rhizome extract in a number of ratios beginning with 1:50:1:1:1:1:1:1:1:1 and increasing or decreasing the relative amount of a component based upon the optimization of these screening assays. Optimal fractional composition of F105 was determined to be 8.5%, 70.4%, 1.4%, 1.4%, 1.4%, 1.4%, 4.2%, 1.4%, 1.4%, and 8.5%, respectively for the 10 components.
BFE
The dehydrated BFE used in these studies contained 30% bergamot flavanoids.
Chemicals and reagents
2=2=-Azobis-(2-amidinopropane)-dihydrochloride (AAPH), fluorescein, DL-penicillamine, sodium hydroxide, potassium phosphate buffer, methanol, and acetone were purchased from Fisher Scientific (Waltham, Massachusetts, USA). Peroxynitrite was purchased from Calbiochem (Billerica, Massachusetts, USA). DHR123 (dihydrorhodamine 123), DTPA (diethylenetriaminepentaacetic acid), and all other chemicals were purchased from Sigma-Aldrich (St. Louis, Missouri, USA) and were of the highest purity available.
Antioxidant and enzyme assays
ORAC, free radical quenching capacity of 2,2-diphenyl-1picrylhydrazyl (DPPH), and ONOO − scavenging capacity assays were performed according to previously published methods with the modification that all were adapted to 96-well microtiter plates (Dudonné et al. 2009; Kim et al. 2008; Prior et al. 2003) . The ONOO − scavenging capacity was measured by a modified method that was described previously (Kim et al. 2008) . Trolox was the positive control for the ORAC and DPPH assays and DL-penicillamine was used as a positive control for ONOO − scavenging assays. MPO chlorination activity assays were performed according to the manufacturer's instructions (Item No. 700170; Cayman Chemicals, Ann Arbor, Michigan, USA) without modification.
The ability of the subjects' plasma to inhibit MPO was assessed using the same Cayman Chemicals MPO kit. Plasma samples were filtered through 10 kDa cutoff VivaSpin 500 columns (Sartorius, Bohemia, New York, USA). Filtered plasma was then serially diluted 10 times starting with a 5% concentration and mixed with MPO, hydrogen peroxide, and chlorination substrate in a final reaction volume of 0.1 mL per well in a 96-well microplate. Commercial sodium heparin plasma (BioreclamationIVT, Hocksville, New York, USA) was used at a concentration of 0.25% as a reference, standard plasma. The microplate was incubated on a plate shaker at room temperature for 20 min and the fluorescence was measured on a Cytation 5 plate reader (BioTek Instruments, Winooski, Vermont, USA) with excitation and emission wavelengths of 490 nm and 520 nm, respectively.
Calculations
The median inhibitory concentration (IC 50 ) values for the ORAC, free radical quenching capacity of DPPH, ONOO − scavenging capacity, and MPO inhibition were calculated from doseresponse curves using 10 concentrations and the CalcuSyn (Biosoft, Cambridge, UK) software package. This statistical package performs multiple drug dose-effect calculations using the median effect methods previously described by Chou and Talalay (1984) . The goodness of fit for the data to the median-effect equation was assessed by the linear correlation coefficient r of the median-effect plot. In all cases, r was greater than 0.96.
Synergy of test components was quantified using the combination index (CI) parameter. This parameter defines only the additive effect rather than synergism or antagonism. For mutually exclusive compounds that have the same mode of action or for mutually non-exclusive compounds that have totally independent modes of action, the relationships CI < 1, CI = 1, and CI > 1 indicating antagonism, additivity, and synergy, respectively, were used.
Expected IC 50 values of the multi-component combination was estimated using the relationship:
where Fa is the fraction of component A in the combination and Fn is the fraction of the n th component combination with Fa + Fb + … + Fn = 1 and IC 50A is the observed IC 50 of component A, etc. The CI was then calculated as (Expected IC 50 )/(Observed IC 50 ) of the formulation.
Observational, clinical pilot safety, and efficacy study
A 12-week, observational, one-arm study was conducted with 3 men and 8 women between the ages of 38 to 65 years at the High Desert Heart Institute, Victorville, California, from 10 June 2014 to 10 October 2014. No public advertising was conducted and all subjects were patients of the High Desert Heart Institute. The study protocol was approved by the Copernicus Group Independent Review Board (Durham, North Carolina, USA) and subjects executed informed consent prior to participating in the study. The study was not publicly registered. Criteria for inclusion were body mass index (BMI) > 18 kg/m 2 and < 40 kg/mm 2 ; low density lipoprotein cholesterol (LDLc) ≥ 150 mg/dL and ≤ 350 mg/dL on screening laboratories; and (or) triglycerides (TG) ≥ 150 mg/dL and ≤ 400 mg/dL on screening laboratories.
Exclusion criteria included use of nutritional supplements and medical foods for dyslipidemia, prescription of HMG-CoA reductase inhibitors, bile acid sequestrants, fibrates, cholesterol adsorption blocking agents, niacin, prescription medications and (or) non-prescription medications for acute and semi-acute medical conditions, investigational drug or participation in an investigational study, oral or injectable corticosteroids, anticoagulant medications (heparin compounds, platelet inhibitors, or warfarin) within 30 days prior to Day 0 and for the duration of the study; change in prescription, non-prescription, nutritional supplements and (or) medical foods within 30 days prior to Day 0 and for the duration of the study; use of medications classified as narcotics within 30 days prior to screening and for the duration of the study; a history of allergy or intolerance to study products; clinically significant abnormalities in medical history or physical examination; vital signs (systolic blood pressure < 90 mm Hg or > 160 mm Hg, diastolic blood pressure < 50 mm Hg or > 100 mm Hg, or resting heart rate < 50 or > 100 bpm); clinically significant abnormalities on laboratory examination at screening; serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, immunologic, hematologic disease, or known infection with human immunodeficiency virus (HIV), tuberculosis or hepatitis B or C; a current diagnosis or personal history of any cardiovascular disease (including myocardial infarction, angina, cardiovascular surgery, congestive heart failure, cardiac arrhythmias or conduction abnormalities, cerebrovascular accident, transient ischemic attack (TIA), or peripheral vascular disease, deep vein thrombosis or pulmonary embolus), type 1 diabetes mellitus; any autoimmune disease such as inflammatory bowel disease (including Crohn's disease and (or) ulcerative colitis), multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, polymyositis, scleroderma and (or) thyroiditis; any significant liver or kidney disease (such as cirrhosis or nonalcoholic fatty liver disease), glomerulonephritis, or undergoing dialysis treatment, any malignancy (with the exception of basal or squamous cell carcinoma of the skin if adequately treated and no recurrence for > 5 years); any serious mental illness including a history of attempted suicide; use of drugs of abuse, such as marijuana, cocaine, phencyclidine (PCP), and methamphetamine; and 30 days prior to screening and for the duration of the study or history of regular intake of > 14 alcoholic drinks per week for females, and > 21 drinks per week for males (1 drink = 12 oz. beer, 4 oz. wine, or 1.0 oz. hard liquor).
Informed written consent was obtained from all participants prior to enrollment in the study. The study was conducted in full conformity with the current revision of the Declaration of Helsinki, or with the International Conference for Harmonization Good Clinical Practice regulations and guidelines, whichever affords the greater protection to the subject.
Study procedures
This was a 12-week, open-label, one-arm trial. F105 was dosed at 2 capsules (total 500 mg BFE and 220 mg phytocomplex blend). Subjects were instructed to take the daily dose at dinnertime as clinical studies indicate greater efficacy of HMG-CoA reductase inhibitors with evening dosing (Lund et al. 2002; Wallace et al. 2003) . Clinical visits took place at weeks 0, 4, 8, and 12 with one electronic Visit Questionnaire between the 4-and 8-week clinical visits. Compliance was assessed by pill count of remaining product at visits 2, 3, and 4. Visit procedures included clinical assessment by study physician, review of Visit Questionnaire, vital signs, physical measurements, urine pregnancy test (women of child-bearing potential), blood specimen draw, and distribution of the test material F105. The following blood variables were evaluated: complete blood count (CBC) at weeks 0 and 12; complete metabolic panel (CMP) at weeks 0 and 12; fasting lipid panel (total cholesterol (TC), TG, high density lipoprotein cholesterol (HDLc), low density lipoprotein (LDLc) [calculated]), oxidized low density lipoprotein (oxLDL), myeloperoxidase (MPO), plasminogen activator inhibitor-1 (PAI-1), and hemoglobin A1c (HbA1c) were done at weeks 0, 4, and 12. CBC and CMP values were done at Quest Diagnostics (Murray, Utah, USA); lipid panel, oxLDL, MPO, PAI-1, and HbA1c were done at the Cleveland Heart Clinic (Cleveland, Ohio, USA).
Post hoc analysis
A post hoc analysis was conducted on subjects with an HbA1c > 5.4% and homeostatic model assessment insulin resistance (HOMA-IR) score > 2 or elevated TG. These criteria have been reported to be prognostic of pre-or undiagnosed metabolic syndrome and diabetes. As such, these individuals represent candidates for early intervention with dietary and lifestyle modifications (Cohen et al. 2010; Ginde et al. 2008; Zhuo et al. 2012) . When initial cardiometabolic variables were compared between the 2 groups, no statistically significant differences were noted (Table 1) .
Individual case management report with F105
Clinical history
A 70-year-old woman presented with the following clinical profile, consistent with the diagnosis of metabolic syndrome (Alberti et al. 2006) : systolic blood pressure (SBP) > 150 mm Hg, BMI = 34.7 at body mass of 189.6 lbs, fasting blood glucose = 150 mg/dL, TG > 150 mg/dL, and HDL < 50 mg/dL. Her previous medical history also included hypertension, dyslipidemia, type 2 diabetes, colonic inertia status post total colectomy and ileostomy, recurrent his-tory of intestinal pseudo-obstruction, biliary dyskinesia, cholecystitis, which required cholecystectomy, biliary duct stenosis, status post biliary and pancreatic sphincterectomies, vitamin B12 deficiency, migraine headaches, interstitial pneumonitis, and depression.
Intervention
The patient was prescribed a low glycemic Mediterranean food plan and physical activity consisting of 250 min of exercises per week: aerobic exercises, 175 min per week; anaerobic exercises, 15 min 3 times per week; stretching exercises, 10 min 3 times per week. She continued taking 20 mg simvastatin daily during this time. Lifestyle and diet modifications resulted in a 39 lb reduction in body mass, a 30-point reduction in SBP, and a reduction of fasting glucose to 105 mg/dL over a 5-year period. Lipid biomarkers, however, remained unchanged by either lifestyle modifications or the statin treatment. At this time, the subject was directed to take 720 mg of the F105 formulation daily with her evening meal, consistent with trial subjects, for 12 weeks. Her initial cardiometabolic values prior to this treatment period were: mass = 133 lbs, BMI = 24.0 kg/m 2 , TC = 241 mg/dL, LDL = 140 mg/dL, TG = 301 mg/dL, HDL = 41 mg/dL, non-HDL = 200 mg/dL, oxLDL = 36 U/L, TC/HDL = 5.9, LDL/HDL = 3.4, TG/HDL = 7.3, oxLDL/HDL = 0.88, lipoproteinassociated phospholipase A2 (LP-PLA2) = 141 ng/mL, HbA1c = 6.0%, and glucose = 102 mg/dL.
Statistical methods
The non-parametric Wilcoxon Signed Ranks test of the [log(baseline/ 12-week)] ratio was used to compare the medians between paired samples using GraphPad Prism (GraphPad Software, San Diego, California, USA). The null hypothesis that the median change from baseline of the 2 groups was zero was rejected at the nominal 5% level using a two-tailed test. Tabulated median percent changes reflect the median of the individual (week 12 minus baseline) changes for each test variable. The Mann-Whitney U test was used to assess and potential initial differences between all subjects and the ad hoc subset of subjects with HbA1c > 5.4 and HOMA-IR score > 2 or elevated TG.
Results
In vitro studies
With a 2.5-fold increase in ORAC, a 6.1-fold increase in DPPH, and a 3.3-fold inhibition of ONOO − formation, F105 exhibited a dramatic increase in antioxidant activity relative to the BFE alone (Table 2) . Additionally, the CI values of 1.42 and 1.65 indicated a synergistic effect among the F105 components for ORAC and inhibition of ONOO − formation, respectively. Among the 10 components, the BFE exhibited consistent, albeit generally modest, inhibitory activity and was more potent than the penicillamine positive control in the ONOO − scavenging assay. The grape seed extract was among the most potent inhibitors in all 3 assays and green tea leaf extract appeared relatively specific for ONOO − inhibition. Both of these phytoextracts were the only components more potent than trolox in the DPPH assay and were highest in potency among the other 8 phytoextracts and positive control penicillamine in the ONOO − scavenging assay.
The BFE was the poorest inhibitor of MPO among the 10 F105 phytoextracts. When combined with the other 9 components, however, MPO inhibition was increased 14-fold as did the F105 (Table 3 ). This level of increase in potency was accompanied by a synergistic inhibitory effect of the formulation on MPO inhibition as evidenced by a CI of 3.39. As seen with ONOO − inhibition, the green tea leaf extract was the most potent single ingredient as an MPO inhibitor with an IC 50 of 0.883 g/mL.
Clinical observations of F105 on cardiometabolic variables
All 11 subjects completed the 12-week study and no adverse events related to F105 were reported. Aside from a statistically significant 4.76% decrease in Mg (p = 0.027), which remained within normal limit, the complete blood counts and metabolic profiles did not differ (P > 0.05) at the end of the study from baseline (Table 4) .
Among the cardiometabolic variables for all subjects (Table 5) , statistically significant changes were noted in total cholesterol (−7.3%), LDL-cholesterol (−10%), non-HDL cholesterol (−7.1%), cholesterol/HDL (−26%), and apolipoprotein B (−2.8%).
The post hoc analysis on the 8 subjects with an HbA1c > 5.4% revealed 6 other statistically significant changes (Table 6 ) in addition to those previously observed in all subjects. Those 6 additional cardiometabolic risk factors modified by F105 in this subgroup included TG (−27%), oxLDL (−19%), LDL/HDL (−25%), TG/ HDL (−27%), oxLDL/HDL (−25%), and PAI-1 (−37%). Ex vivo inhibition of MPO trended from −7.7% to −13% (P > 0.05), respectively, in subjects and subgroup. With the exception of LDL cholesterol, which decreased 10% in both groups, there was a general trend for more improvement in those 8 subgroup subjects at higher risk for cardiovascular disease. Improvements in this subgroup relative to all subjects ranged from −36% for total cholesterol to −73% for cholesterol/HDL (Fig. 1) .
Individual case management report with F105
While statin therapy failed to affect the lipid profile of the patient, F105 daily for 12 weeks was associated with a marked reduction of all cardiometabolic risk factors including a substantive decrease of 39% in oxLDL/HDL (Fig. 2) .
Discussion
Our results presented in this study demonstrate the bona fide synergism of the F105 formulation in different in vitro antioxidant assays. In the present experiments, BFE exhibited only modest activity in the ORAC, DPPH, and MPO inhibition assays with IC 50 values of 46, 379, and 42 g/mL, respectively. Only in the ORAC assay, did BFE perform better than a majority of the other components. A study on the antioxidant activity of Citrus bergamia juice reported a modest, but more potent, effect on DPPH activity with an IC 50 of 25 g/mL (Trovato et al. 2010) . The difference between these results and ours is most likely due to a difference in chemical composition, because the previously reported DPPH assay was performed on liquid bergamot fruit juice and not a fruit juice extract as in this study; but the results may also differ due to geographical source or strain (Statti et al. 2004 ). In general, reports on the polyphenol and flavonoid content of bergamot fruit juice and antioxidant activity in other assays support the potency level of antioxidant activity found in our studies (Picerno et al. 2011; Ramful et al. 2010 ).
Similar to our finding of synergy among the F105 components in the ORAC, ONOO − , and MPO assays, oil of bergamot has been reported to have synergistic effect on total antioxidant activities of black and peppermint teas (Büyükbalci and El 2008) . On a weight basis, the activity of the F105 formulation was improved relative to BFE alone 2.5-to 14-fold, with synergy associated with these increases for ORAC, ONOO − , and MPO inhibition.
Ours is the first study to report a direct inhibitory effect of BFE and F105 components on MPO in vitro. Although the IC 50 of BFE alone was relatively high at 42 g/mL, the IC 50 for the F105 formulation was improved 3.4-fold from an expected 10 g/mL to an observed 2.95 g/mL. The potency of MPO inhibition by F105 was further increased 14-fold over BFE alone, from 42 to 2.95 g/mL. A recent study demonstrated the ability of BFE to inhibit colonic MPO activity in the mouse colitis model (Impellizzeri et al. 2015) . In our own observational trial, ex vivo inhibition of MPO trended from −7.7% to −13% (p > 0.05), respectively, in subjects and subgroup. While this result was not statistically significant, it represented decreases in 7 of the 11 subjects (64%) and 6 of 8 (75%) subgroup subjects and warrants future study. Note: The fractional amounts of each component in F105 were in the approximate ratio of 6/50/1/1/1//1/3/1/1/6. Expected IC 50 was estimated using the relationship: (1/Expected IC 50 ) = (Fa/IC 50A ) + (Fb/IC 50B ) + … + (Fn/IC 50N ), where Fn is the fraction of component N in the mixture and the total of the fractions = 1.
*IC 50 reflects the response elicited from a dose-response curve of 10 concentrations of the pure component; in all cases, r was greater than 0.96. The IC 50 values for the trolox control in the ORAC and DPPH assays were 2.50 and 7.79 g/mL, respectively; the IC 50 for the penicillamine positive control of the peroxynitrite assay was 16.5 g/mL. An important finding of this study is that 12 weeks of F105 treatment regimen is clinically well-tolerated and effective for ameliorating dyslipidemia in human subjects with moderate cardiometabolic risk factors. In all subjects (Table 5) , statistically significant changes were noted in total cholesterol, LDL cholesterol, non-HDL cholesterol, cholesterol/HDL, and apolipoprotein B (Apo B) after receiving F105 for 12 weeks with no mass loss. Moreover, the subgroup representing subjects with HbA1c > 5.4 (Table 6 ) reported improved changes in these variables, but also exhibited dramatic decreases in TG, LDL/HDL, oxLDL, triglyceride/ HDL, and oxLDL/HDL. Additionally, this subgroup was found to have a 37% decrease in PAI-1 levels (Fig. 1) . Ex vivo inhibition of MPO trended from −4.2% to −13%, respectively, in all subjects and subgroup. No statistically significant effects or trends were seen in fasting glucose, fasting insulin, HbA1c or HOMA-IR, or homeostatic model assessment beta-cell function (HOMA-␤). The 27% decrease in TG/HDL (p = 0.039), however, can be interpreted as supporting glycemic control by F105 in prediabetic individuals (Vega et al. 2014; Zonszein et al. 2015) in addition to its usefulness in assessing cardiovascular disease severity and predictive value in new-onset heart failure (Yunke et al. 2014) .
Our subgroup also demonstrated favorable responses in other biomarkers associated with severity or changes associated with CAD. For example, levels of ApoB have been associated with the increased carotid intima-media thickness, (Huang et al. 2013 ) and LDL/HDL is an independent predictor of vulnerable coronary plaque (Fujihara et al. 2013) . PAI-1, a principal inhibitor of fibrinolysis, is induced in thrombotic, fibrotic, and cardiovascular diseases, which in turn primarily afflict the older population. PAI-1 may also play a critical role in the development of aging-associated pathological changes associated with CAD (Yamamoto et al. 2014) . Early work has indicated that PAI-1 can be upregulated through oxidative stress (Vulin and Stanley 2004) and inflammation (Alessi and Juhan-Vague 2004; Song et al. 2005) . Hence, significant inhibition of PAI-1 by F105 supplementation would be of benefit in attenuating the deterioration of vessels particularly in a subset of subjects with initial HbA1c > 5.4 and one additional cardiometabolic risk factor.
Ours is the first study to report a favorable effect of a BFE formulation on oxLDL and oxLDL/HDL, which are considered more predictive of both cardiovascular and diabetic risk than traditional lipid or glycemic markers (Johnston et al. 2006; Kaikkonen et al. 2016; Mascarenhas-Melo et al. 2013; Mitra et al. 2011b ). Decreases in both biomarkers trended to greater efficacy and statistical significance in the subgroup relative to all subjects, decreasing from −10% to −19% and from −17% to −25%, respectively. To our knowledge, this is the first report on novel biological activity of BFE formulation. Moreover, our in vitro pilot clinical results and individual case management are consistent with previously proposed antioxidant and anti-inflammatory mechanisms of BFE vasoprotective effects (Gliozzi et al. 2014b ) and represent the first clinical trial of a BFE formulation performed outside of Italy. In vitro, F105 demonstrated enhanced antioxidant and MPO inhibitory activity over BFE alone. Clinically, F105 reduced biomarkers associated with inflammation including oxLDL, oxLDL/ HDL (Tekin et al. 2013) , PAI-1 (Iwaki et al. 2012) , and glycemic control such as TG/HDL (Vega et al. 2014; Zonszein et al. 2015) in subjects with only moderate elevations in cardiometabolic risk factors and can represent consideration for first line therapy along with diet and exercise. While decreases in cardiometabolic variables reported here in the total group of 11 subjects tended to be somewhat lower than those reported elsewhere, those studies either used doses nearly twice as high (Gliozzi et al. 2014a) or enrolled subjects satisfying complete diagnostic criteria for metabolic syndrome (Gliozzi et al. 2014b) . Simply put, they were at a higher cardiometabolic risk stage and as seen with many therapeutics, response is typically greater in this type of subject population. That said, this increasing effectiveness in higher risk individuals was also seen in our subgroup analysis as well, which showed greater, statistically significant changes in subjects with the highest (e.g., Hb1c > 5.4) cardiometabolic risk factors (Table 6 ). When subjects with only moderate elevations in LDL or TG are studied, sample sizes need to be much larger to achieve statistical significance with the commonly used 80% probability. For example, a power analysis of our data indicated that you would need approximately 78 subjects to achieve statistical significance for the observed 10% and 17% decreases in oxLDL and oxLDL/HDL, respectively, in the total group of 11 subjects (Table 5) .
While the patient responded favorably to diet and lifestyle change with respect to reductions in body mass, blood pressure and plasma glucose, lipid biomarkers, however, remained unchanged by statin therapy. The dramatic reduction in lipid biomarkers by F105 in this patient supports further hypolipidemic actions beyond inhibition of HMG-CoA reductase.
Conclusion
Our in vitro studies indicate that BFE can play a central role in the development of synergistic, biologically active blends of phy-toextracts. Further, enhanced peroxynitrite scavenging and MPO inhibition may broaden BFE potential usefulness for cardiometabolic disorders. Clinically, the F105 supplementation regimen demonstrated safety and efficacy in subjects with moderate signs of CAD risk factors in our 12-week, observational trial. The subgroup of subjects with increased risk of developing metabolic syndrome and diabetes exhibited further improvement in similar cardiometabolic variables as well as dramatic lowering of TG, ox-LDL, and PAI-1, and TG/HDL, oxLDL/HDL, oxLDL/HDL ratios. It is also of note that successful lowering of lipid biomarkers in a patient nonresponsive to statin therapy suggests F105 extends the potential mechanisms of action of BFE beyond the purported inhibition of HMG-CoA reductase. Fig. 1 . Decreases in cardiometabolic variables seen in the hemoglobin A1c (HbA1c) > 5.4 subgroup not significantly affected in all subjects. Statistical significance was computed using the log-normal distribution of the ratio of baseline to 12 weeks using the Wilcoxon Signed Rank test. HbA1c > 5.4 subgroup consisted of 8 subjects with HbA1c > 5.4 and homeostatic model assessment insulin resistance (HOMA-IR) score > 2 or elevated triglycerides (TG). N = 11 for all subjects and N = 8 for subgroup. HDL, high density lipoprotein; LDL, low density lipoprotein; oxLDL, oxidized low density lipoprotein; PAI-1, plasminogen activator inhibitor type 1.
Fig. 2. Changes in cardiometabolic variables exhibited by a
70-year-old female following 12 weeks of daily supplementation with 720 mg F105. The subject was nonresponsive to 20 mg simvastatin over a prior 5-year period. Initial cardiometabolic values for this subject preceding this treatment period were mass = 133 lbs, BMI = 24.0 kg/m 2 , TC = 241 mg/dL, LDL = 140 mg/dL, TG = 301 mg/dL, HDL = 41 mg/dL, non-HDL = 200 mg/dL, oxLDL = 36 U/L, TC/HDL = 5.9, LDL/HDL = 3.4, TG/HDL = 7.3, oxLDL/HDL = 0.88, LP-PLA2 = 141 ng/mL, HbA1c = 6.0%, and glucose = 102 mg/dL. BMI, body mass index; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; LP-PLA2, lipoprotein-associated phospholipase A2; oxLDL, oxidized low density lipoprotein; PAI-1, plasminogen activator inhibitor type 1; TC, total cholesterol; TG, triglycerides.
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